Quinapril in patients with congestive heart failure: Controlled trial versus captopril

Domenico Acanfora, Giuseppe Furgi, Luigi Trojano, Costantino Picone, Gian Luca Iannuzzi, Michele Rossi, Antimo Papa, Carlo Rengo, Franco Rengo

Research output: Contribution to journalArticle

Abstract

After two weeks of a wash-out run-in period with placebo, 131 patients with congestive heart failure (New York Heart Association [NYHA] class II to III) and left ventricular ejection fraction ≤40% were randomly assigned to a treatment period of 4 weeks with 10 mg quinapril once daily or 12.5 mg captopril twice daily. At the end of this period, doses were titrated to 20 mg quinapril once daily or 25 mg captopril twice daily on the basis of physician judgment if there were no major adverse reactions and if blood pressure was not below 110/70 mm Hg. Clinical symptoms of heart failure were significantly relieved by both drugs at the end of a 12-week treatment period. At the beginning of the study, 23 (35%) of the 65 patients taking quinapril and 27 (41%) of the 66 patients taking captopril were in NYHA functional class III, whereas, at the end of the trial, only 4 (6%) of the patients in the quinapril group and 14 (22%; p <0.05 versus quinapril) patients in the captopril group were classified as NYHA class III. Both drugs had a positive effect on echocardiographic parameters. There was a statistically significant increase in exercise duration in both treatment groups (quinapril, 6.2 ± 1.8 versus 7.8 ± 1.9 minutes, p <0.001; captopril, 5.9 ± 1.9 versus 7.1 ± 2.3 minutes, p <0.001). One patient in the quinapril group died suddenly during the study and two patients in the captopril group dropped out of the study due to persistent dry cough. No patient in the quinapril group reported side effects. Three patients in the captopril group suffered from moderate dry cough, one from taste-blindness, and another from unstable angina. The safety of the tested drugs was confirmed by laboratory tests. Quinapril was as effective as captopril in reducing signs and symptoms of heart failure and in improving the left ventricular function and the exercise capacity with few side effects.

Original languageEnglish
Pages (from-to)181-188
Number of pages8
JournalAmerican Journal of Therapeutics
Volume4
Issue number5-6
Publication statusPublished - May 1997

Fingerprint

Captopril
Heart Failure
Cough
Ageusia
Pharmaceutical Preparations
Exercise
quinapril
Unstable Angina
Left Ventricular Function
Stroke Volume
Signs and Symptoms
Therapeutics
Placebos
Blood Pressure
Physicians
Safety

Keywords

  • Captopril
  • Congestive heart failure
  • Exercise capacity
  • Left ventricular ejection fraction
  • Quinapril

ASJC Scopus subject areas

  • Pharmacology

Cite this

Acanfora, D., Furgi, G., Trojano, L., Picone, C., Iannuzzi, G. L., Rossi, M., ... Rengo, F. (1997). Quinapril in patients with congestive heart failure: Controlled trial versus captopril. American Journal of Therapeutics, 4(5-6), 181-188.

Quinapril in patients with congestive heart failure : Controlled trial versus captopril. / Acanfora, Domenico; Furgi, Giuseppe; Trojano, Luigi; Picone, Costantino; Iannuzzi, Gian Luca; Rossi, Michele; Papa, Antimo; Rengo, Carlo; Rengo, Franco.

In: American Journal of Therapeutics, Vol. 4, No. 5-6, 05.1997, p. 181-188.

Research output: Contribution to journalArticle

Acanfora, D, Furgi, G, Trojano, L, Picone, C, Iannuzzi, GL, Rossi, M, Papa, A, Rengo, C & Rengo, F 1997, 'Quinapril in patients with congestive heart failure: Controlled trial versus captopril', American Journal of Therapeutics, vol. 4, no. 5-6, pp. 181-188.
Acanfora D, Furgi G, Trojano L, Picone C, Iannuzzi GL, Rossi M et al. Quinapril in patients with congestive heart failure: Controlled trial versus captopril. American Journal of Therapeutics. 1997 May;4(5-6):181-188.
Acanfora, Domenico ; Furgi, Giuseppe ; Trojano, Luigi ; Picone, Costantino ; Iannuzzi, Gian Luca ; Rossi, Michele ; Papa, Antimo ; Rengo, Carlo ; Rengo, Franco. / Quinapril in patients with congestive heart failure : Controlled trial versus captopril. In: American Journal of Therapeutics. 1997 ; Vol. 4, No. 5-6. pp. 181-188.
@article{0b132e5aba7848b8b415fa689e5c461a,
title = "Quinapril in patients with congestive heart failure: Controlled trial versus captopril",
abstract = "After two weeks of a wash-out run-in period with placebo, 131 patients with congestive heart failure (New York Heart Association [NYHA] class II to III) and left ventricular ejection fraction ≤40{\%} were randomly assigned to a treatment period of 4 weeks with 10 mg quinapril once daily or 12.5 mg captopril twice daily. At the end of this period, doses were titrated to 20 mg quinapril once daily or 25 mg captopril twice daily on the basis of physician judgment if there were no major adverse reactions and if blood pressure was not below 110/70 mm Hg. Clinical symptoms of heart failure were significantly relieved by both drugs at the end of a 12-week treatment period. At the beginning of the study, 23 (35{\%}) of the 65 patients taking quinapril and 27 (41{\%}) of the 66 patients taking captopril were in NYHA functional class III, whereas, at the end of the trial, only 4 (6{\%}) of the patients in the quinapril group and 14 (22{\%}; p <0.05 versus quinapril) patients in the captopril group were classified as NYHA class III. Both drugs had a positive effect on echocardiographic parameters. There was a statistically significant increase in exercise duration in both treatment groups (quinapril, 6.2 ± 1.8 versus 7.8 ± 1.9 minutes, p <0.001; captopril, 5.9 ± 1.9 versus 7.1 ± 2.3 minutes, p <0.001). One patient in the quinapril group died suddenly during the study and two patients in the captopril group dropped out of the study due to persistent dry cough. No patient in the quinapril group reported side effects. Three patients in the captopril group suffered from moderate dry cough, one from taste-blindness, and another from unstable angina. The safety of the tested drugs was confirmed by laboratory tests. Quinapril was as effective as captopril in reducing signs and symptoms of heart failure and in improving the left ventricular function and the exercise capacity with few side effects.",
keywords = "Captopril, Congestive heart failure, Exercise capacity, Left ventricular ejection fraction, Quinapril",
author = "Domenico Acanfora and Giuseppe Furgi and Luigi Trojano and Costantino Picone and Iannuzzi, {Gian Luca} and Michele Rossi and Antimo Papa and Carlo Rengo and Franco Rengo",
year = "1997",
month = "5",
language = "English",
volume = "4",
pages = "181--188",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "5-6",

}

TY - JOUR

T1 - Quinapril in patients with congestive heart failure

T2 - Controlled trial versus captopril

AU - Acanfora, Domenico

AU - Furgi, Giuseppe

AU - Trojano, Luigi

AU - Picone, Costantino

AU - Iannuzzi, Gian Luca

AU - Rossi, Michele

AU - Papa, Antimo

AU - Rengo, Carlo

AU - Rengo, Franco

PY - 1997/5

Y1 - 1997/5

N2 - After two weeks of a wash-out run-in period with placebo, 131 patients with congestive heart failure (New York Heart Association [NYHA] class II to III) and left ventricular ejection fraction ≤40% were randomly assigned to a treatment period of 4 weeks with 10 mg quinapril once daily or 12.5 mg captopril twice daily. At the end of this period, doses were titrated to 20 mg quinapril once daily or 25 mg captopril twice daily on the basis of physician judgment if there were no major adverse reactions and if blood pressure was not below 110/70 mm Hg. Clinical symptoms of heart failure were significantly relieved by both drugs at the end of a 12-week treatment period. At the beginning of the study, 23 (35%) of the 65 patients taking quinapril and 27 (41%) of the 66 patients taking captopril were in NYHA functional class III, whereas, at the end of the trial, only 4 (6%) of the patients in the quinapril group and 14 (22%; p <0.05 versus quinapril) patients in the captopril group were classified as NYHA class III. Both drugs had a positive effect on echocardiographic parameters. There was a statistically significant increase in exercise duration in both treatment groups (quinapril, 6.2 ± 1.8 versus 7.8 ± 1.9 minutes, p <0.001; captopril, 5.9 ± 1.9 versus 7.1 ± 2.3 minutes, p <0.001). One patient in the quinapril group died suddenly during the study and two patients in the captopril group dropped out of the study due to persistent dry cough. No patient in the quinapril group reported side effects. Three patients in the captopril group suffered from moderate dry cough, one from taste-blindness, and another from unstable angina. The safety of the tested drugs was confirmed by laboratory tests. Quinapril was as effective as captopril in reducing signs and symptoms of heart failure and in improving the left ventricular function and the exercise capacity with few side effects.

AB - After two weeks of a wash-out run-in period with placebo, 131 patients with congestive heart failure (New York Heart Association [NYHA] class II to III) and left ventricular ejection fraction ≤40% were randomly assigned to a treatment period of 4 weeks with 10 mg quinapril once daily or 12.5 mg captopril twice daily. At the end of this period, doses were titrated to 20 mg quinapril once daily or 25 mg captopril twice daily on the basis of physician judgment if there were no major adverse reactions and if blood pressure was not below 110/70 mm Hg. Clinical symptoms of heart failure were significantly relieved by both drugs at the end of a 12-week treatment period. At the beginning of the study, 23 (35%) of the 65 patients taking quinapril and 27 (41%) of the 66 patients taking captopril were in NYHA functional class III, whereas, at the end of the trial, only 4 (6%) of the patients in the quinapril group and 14 (22%; p <0.05 versus quinapril) patients in the captopril group were classified as NYHA class III. Both drugs had a positive effect on echocardiographic parameters. There was a statistically significant increase in exercise duration in both treatment groups (quinapril, 6.2 ± 1.8 versus 7.8 ± 1.9 minutes, p <0.001; captopril, 5.9 ± 1.9 versus 7.1 ± 2.3 minutes, p <0.001). One patient in the quinapril group died suddenly during the study and two patients in the captopril group dropped out of the study due to persistent dry cough. No patient in the quinapril group reported side effects. Three patients in the captopril group suffered from moderate dry cough, one from taste-blindness, and another from unstable angina. The safety of the tested drugs was confirmed by laboratory tests. Quinapril was as effective as captopril in reducing signs and symptoms of heart failure and in improving the left ventricular function and the exercise capacity with few side effects.

KW - Captopril

KW - Congestive heart failure

KW - Exercise capacity

KW - Left ventricular ejection fraction

KW - Quinapril

UR - http://www.scopus.com/inward/record.url?scp=0030940230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030940230&partnerID=8YFLogxK

M3 - Article

C2 - 10423609

AN - SCOPUS:0030940230

VL - 4

SP - 181

EP - 188

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 5-6

ER -